<DOC>
	<DOCNO>NCT00039325</DOCNO>
	<brief_summary>RATIONALE : Vaccines make insert laboratory-treated gene person 's white blood cell may make body build immune response kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose vaccine therapy see well work treat patient stage IV recurrent malignant melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage IV Recurrent Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria This study confine adult age 18 histologically proven malignant melanoma . MART1 , assess either RTPCR immunohistochemistry . Subjects must type HLAA*0201 phase I part study , HLAA*0201 and/or DR*04 phase II part . Stage unresectable measurable melanoma ( stage IV stage III unresectable ) . Patients previously treat form therapy ( include chemotherapy , radiation therapy , immunotherapy surgery ) either metastatic , relapsed primary melanoma eligible trial , provide previous previous treatment complete &gt; 30 day prior first vaccine . Both male female patient may enrol . Premenopausal females must negative pregnancy test prior treatment . Karnofsky Performance Status great equal 70 percent , ECOG great 2 . No previous evidence class 3 great New York Heart Association cardiac insufficiency coronary artery disease . No previous evidence opportunistic infection . A minimum 30 day must elapse since completion prior chemotherapy , immunotherapy radiation therapy . Adequate baseline hematological function assess follow laboratory value within 30 day prior study entry : Hemoglobin &gt; 9.0 g/dl . Platelets &gt; 100,000/mm3 . WBC &gt; 3,000/mm3 . Absolute Neutrophil Count ( ANC ) &gt; 1,000/mm3 . Ability give inform consent . Exclusion Criteria Patients meet one follow criterion exclude study entry : Lactating female : Females childbearing potential ( premenopausal ) must negative serum betaHCG pregnancy test ( within Day 7 Day 0 ) . Acute infection : acute viral , bacterial , fungal infection require specific therapy . Acute therapy must complete within 14 day prior study treatment . HIVinfected patient , due concern ability stimulate effective immune response . Acute medical problem ischemic heart lung disease may consider unacceptable anesthetic operative risk . Patients underlying condition would contraindicate therapy study treatment ( allergy reagent ) . Patients organ allograft . Uncontrolled CNS metastasis . Patients CNS metastasis eligible receive CNS irradiation control local tumor growth . Previous clinical evidence autoimmune disease . Concomitant Medication Treatment All allow medication treatment keep minimum record . All question regard concomitant medication refer study chair investigator . Medications Treatments Not Allowed Corticosteroids Chemotherapy Cyclosporin A .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>